<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>364-MODAFINIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>364-MODAFINIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use oral contraceptives containing estrogens and progestins that have 50 micrograms of estrogen or another method of contraception. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>364-MODAFINIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SOFOSBUVIR" rxcui="">
<ATC code="J05AX15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
